$HRTX

$0.30 -$0.00 (0.69%) Close

$HRTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 189.9M shares outstanding

Who owns HRTX?

By type of holder

Institutions 70.3% Insiders 5.7% Everyone else 24.1%

Concentration Top 10 holders own 65.5%

Rubric Capital Management LP 15.8% · David Rosen 15.8%

Institutional ownership

70.3%

-12.4 pts vs last qtr

Institutional holders

162

-5 vs last qtr

Net shares bought

−23.5M

by institutions in Q2 2026

New / sold out

22 / 27

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Marshall Wace, LLP NEW +2.4M
Qube Research & Technologies Ltd +990.7K

Biggest sellers in Q2 2026

Orbimed Advisors LLC SOLD OUT −9.8M
Palisade Capital Management, LP SOLD OUT −6.1M

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Heron Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2021–FY2025

+169195.5%

+541.45% a year

Each share's claim on the business

−99.9%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $146M

over 5 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years37% 3–5 years52% 1–3 years3% Under 1 year8%

Quarterly turnover

14.8%

of institutional shares changed hands

Top 10 managers, median time held

4.5 years

Super Investors

Investment managers reporting HRTX on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
RC Rubric Capital Management LP 13D · 15.9%	30.0M	15.83%	Unchanged	2022	0.1%
Shares held by quarter Peak holding30.0M (Q4'25) Change over 8 quarters+3.3M Share of the company15.830% Disclosed stake13D · 15.9% Rubric Capital Management LP's full portfolio →
CC Clearline Capital LP	11.4M	6.00%	−851.3K (−7.0%)	2022	0.3%
Shares held by quarter Peak holding12.2M (Q4'25) Change over 8 quarters+9.2M Share of the company6.000% Clearline Capital LP's full portfolio →

Rubric Capital Management LP

13D · 15.9%

30.0M

% of company

15.83%

Change vs last qtr

Unchanged

Held since

2022

Clearline Capital LP

11.4M

% of company

6.00%

Change vs last qtr

−851.3K (−7.0%)

Held since

2022

28 more super investors behind a free account

See every manager holding Heron Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting HRTX on Form N-PORT; together they hold 12.7% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$2.34M	5.5M	2.88%	0.00%	June 30, 2026
IR iShares Russell 2000 ETF iShares Trust	$1.57M	3.7M	1.94%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$2.34M

% of company

2.88%

% of the fund

0.00%

As of

June 30, 2026

iShares Russell 2000 ETF

iShares Trust

Position value

$1.57M

% of company

1.94%

% of the fund

0.00%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Heron Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
DR David Rosen 5%+ holder 13D · 15.9%	30.0M	15.83%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company15.830% Disclosed stake13D · 15.9% View the 13D/G filing →
MA Morgan Adam Insider	8.9M	4.68%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company4.680% Morgan Adam's insider activity →

David Rosen

5%+ holder13D · 15.9%

30.0M

% of company

15.83%

Change vs last qtr

—

Held since

—

Morgan Adam

Insider

8.9M

% of company

4.68%

Change vs last qtr

—

Held since

—

10 more holders behind a free account

See every insider and 5%+ holder of Heron Therapeutics Inc.

Comments